Mylan Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1961-01-01
- Employees
- 35K
- Market Cap
- -
- Website
- https://www.mylan.com/
Clinical Trials
53
Active:4
Completed:45
Trial Phases
6 Phases
Early Phase 1:1
Phase 1:11
Phase 2:6
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (42 trials with phase data)• Click on a phase to view related trials
Phase 3
20 (47.6%)Phase 1
11 (26.2%)Phase 2
6 (14.3%)Not Applicable
2 (4.8%)Phase 4
2 (4.8%)Early Phase 1
1 (2.4%)Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 924
- Registration Number
- NCT05158972
- Locations
- 🇭🇰
Hong Kong ENT Clinic, Hong Kong, Hong Kong
🇭🇰Asia Priority Healthcare, Kowloon, Hong Kong
🇲🇾Kempas Medical Center, Johor Bahru, Malaysia
Study to Evaluate the Effectiveness of Legalon®
Recruiting
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Drug: Legalon® 140 mg
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 362
- Registration Number
- NCT05051527
- Locations
- 🇹🇭
Phramongkutklao Hospital, 315 Ratchawithi Rd, Thung Phaya Thai, Ratchathewi, Bangkok, Thailand
Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)
Early Phase 1
Completed
- Conditions
- HIV-1-infection
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT05030025
- Locations
- 🇨🇦
Altasciences, Montréal, Quebec, Canada
Observation of the Effects of Guideline-driven Lifestyle Interventions, Including Use of a Red-yeast Based Nutraceutical
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 259
- Registration Number
- NCT05000541
- Locations
- 🇦🇹
Ordination, Vienna, Austria
🇩🇪Medical Practice, Görlitz, Germany
🇩🇪AmBeNet GmbH, Leipzig, Germany
Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT04976868
- Locations
- 🇨🇳
Beijing children's Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing Hospital, Beijing, China
🇨🇳Children's Hospital Capital Institute of Pediatrics, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
No news found